Jedzada Maneechavakajorn

Learn More
OBJECTIVE To determine the prognostic value for survival of various pretreatment characteristics and treatments in advanced non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHOD The retrospective study was conducted by reviewing the 81 files of advanced NSCLC patients treated with chemotherapy at the Oncology Unit, Rajavithi Hospital. Eighteen(More)
Research on quality of life (QOL) in Thailand is still in its developing stages and requires cross-culturally valid QOL questionnaires to appropriately assess QOL as an endpoint in research and clinical trials. The English-language version of the FACT-G (Version 4) questionnaire was translated into Thai using an iterative forward-backward translation(More)
OBJECTIVE To determine the prognostic value for survival of pretreatment characteristics and treatments in stage 1-IV colorectal cancer (CRC) patients. MATERIAL AND METHOD The present retrospective cohort study was conducted by reviewing 287files of stage I-IV CRC patients. Fifteen clinical variables were investigated through analysis as prognostic(More)
BACKGROUND Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428) to investigate the efficacy and safety of afatinib, an irreversible(More)
OBJECTIVE To determine the survival duration of stage I-III breast cancer patients, and to determine prognostic factors for overall survival and disease-free survival in stage I to III breast cancer patients treated with surgery and adjuvant therapy. MATERIAL AND METHOD This retrospective cohort study was conducted by reviewing 166files of stage I-III(More)
A prospective phase II study was conducted to determine the response, toxicity and survival rate of lung cancer patients treated with combination paclitaxel and carboplatin in stage IIIB and IV NSCLC. Eligible patients required measurable and/or evaluable diseases; performance status (ECOG) 0-2; no previous chemotherapy; adequate hepatic, renal and bone(More)
  • 1